Dr. Lotan on the iodine-based contrast media shortage

“For patients who are several years out from treatment for bladder cancer or kidney cancer, I don't think [the shortage is] going to have a clinical impact. For more acute settings, I have tried to rely a little bit more on MR urograms and ultrasound,” says Yair Lotan, MD.

Related Videos

Related Content

Advertisement

March 4th 2022

Efficacy of batiraxcept/cabozantinib combo in clear cell RCC: Updated results

Janelle Hart

February 7th 2022

Dr. Lacouture on managing dermatological adverse events with apalutamide in prostate cancer

Janelle Hart

To investigate the severity and prevalence of dermatologic adverse events associated with apalutamide, Mario E. Lacouture, MD, and investigators conducted a study that will help to manage and counsel patients with prostate cancer in the future, especially with the expanded approval of apalutamide in this space.

February 2nd 2022

How appropriate use criteria for PSMA-PET imaging optimize patient care

Janelle Hart

In a recent interview, Hossein Jadvar, MD, PhD, discussed what the appropriate use criteria consist of for prostate-specific membrane antigen (PSMA)-PET imaging, and why these criteria are vital in ensuring the individualized care of patients.

November 9th 2021

Dr. Chee summarizes latest Optilume data in patients with urethral strictures

Urology Times staff

"Certainly, the Optilume drug-coated balloon appears to be safe and effective in roughly two-thirds of patients at 3 years," said Justin Chee, MD.

December 16th 2020

Dr. Declan G. Murphy describes the background of PSMA PET/CT in prostate cancer

Urology Times staff

Murphy shares the backstory of how PSMA PET/CT imaging has emerged as a major advancement in the prostate cancer armamentarium.

June 11th 2020

Dr. Padmanabhan discusses impact of COVID-19

Urology Times® Editorial Council Member Priya Padmanabhan, MD, MPH, professor of urology at Oakland University William Beaumont School of Medicine, Royal Oak, Michigan, discusses how she has been affected by the coronavirus disease 2019 (COVID-19) pandemic.

Related Content

Advertisement

March 4th 2022

Efficacy of batiraxcept/cabozantinib combo in clear cell RCC: Updated results

Janelle Hart

February 7th 2022

Dr. Lacouture on managing dermatological adverse events with apalutamide in prostate cancer

Janelle Hart

To investigate the severity and prevalence of dermatologic adverse events associated with apalutamide, Mario E. Lacouture, MD, and investigators conducted a study that will help to manage and counsel patients with prostate cancer in the future, especially with the expanded approval of apalutamide in this space.

February 2nd 2022

How appropriate use criteria for PSMA-PET imaging optimize patient care

Janelle Hart

In a recent interview, Hossein Jadvar, MD, PhD, discussed what the appropriate use criteria consist of for prostate-specific membrane antigen (PSMA)-PET imaging, and why these criteria are vital in ensuring the individualized care of patients.

November 9th 2021

Dr. Chee summarizes latest Optilume data in patients with urethral strictures

Urology Times staff

"Certainly, the Optilume drug-coated balloon appears to be safe and effective in roughly two-thirds of patients at 3 years," said Justin Chee, MD.

December 16th 2020

Dr. Declan G. Murphy describes the background of PSMA PET/CT in prostate cancer

Urology Times staff

Murphy shares the backstory of how PSMA PET/CT imaging has emerged as a major advancement in the prostate cancer armamentarium.

June 11th 2020

Dr. Padmanabhan discusses impact of COVID-19

Urology Times® Editorial Council Member Priya Padmanabhan, MD, MPH, professor of urology at Oakland University William Beaumont School of Medicine, Royal Oak, Michigan, discusses how she has been affected by the coronavirus disease 2019 (COVID-19) pandemic.